Investor profile
Eshelman Ventures
Venture fund
Directory portfolio
Companies connected here
2
Funding dates unavailable. Companies listed alphabetically.
- D
Dignify Therapeutics
Latest company funding · —
Develops on-demand drugs that let people with spinal cord injury and other neurological conditions empty the bladder or bowel when they choose. Lead candidate DTI-117, a short-acting peptide, received FDA clearance of its IND in October 2026 for a Phase 1 study funded by the NIH.
Incyclix Bio
Latest company funding · —
Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.
Portfolio coverage reflects public company-investor links tracked in this directory and may not represent the investor's full portfolio.